Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 10/20 | 0.51 |
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273202 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2384187 | 1.00 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2221136 | 0.90 | PPARG (0.61) | PPARAPPARGPPARDSRR | |
| SCHEMBL3861924 | 0.86 | PPARG (0.68) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL9686109 | 0.86 | ALDH1A1 (0.50) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL2037092 | 0.86 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL16672561 | 0.86 | ALDH1A1 (0.55) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL30893016 | 0.85 | PPARA (0.45) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL16672702 | 0.85 | LMNA (0.47) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL9902801 | 0.84 | L3MBTL1 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-25 | — | — | US | disclosed |
| US-11466006-B2 | Dual selective PI3 delta and gamma kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-10-11 | — | — | US | disclosed |
| US-20210032248-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2021-02-04 | — | — | US | disclosed |
| US-10851107-B2 | Dual selective P13 delta and gamma kinase inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2020-12-01 | — | — | US | disclosed |
| EP-2844647-B1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS S A (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10130635-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-20170334914-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-23 | — | — | US | disclosed |
| US-9790224-B2 | Dual selective PI3 delta and gamma kinase inhibitors | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-21 | — | — | US | disclosed |
| EP-3004106-B1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-08-30 | — | — | EP | disclosed |
| EP-3004106-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-9309216-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | RHIZEN PHARMACEUTICALS SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| EP-2844647-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | Rhizen Pharmaceuticals S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20140364447-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195888-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-12-11 | — | — | WO | disclosed |
| WO-2013164801-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038634-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4729/4885SLC1A2 4462/4885SLC1A1 4654/4885 |
| US-20150087699-A1 | NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4738/4885SLC1A2 4570/4885SLC1A1 4712/4885 |
| US-20210032248-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | PRKCZ, PIK3CD, PRKCE | SLC1A3 3731/4885SLC1A2 3833/4885SLC1A1 3851/4885 |
| US-11478481-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4729/4885SLC1A2 4462/4885SLC1A1 4654/4885 |
| US-10851107-B2 | Dual selective P13 delta and gamma kinase inhibitors | PRKCZ, PRKCH, PRKCG | SLC1A3 2161/4885SLC1A2 3303/4885SLC1A1 2865/4885 |
| US-11466006-B2 | Dual selective PI3 delta and gamma kinase inhibitors | PRKCZ, PIK3CD, PRKCE | SLC1A3 3731/4885SLC1A2 3833/4885SLC1A1 3851/4885 |
| US-20180098994-A9 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4729/4885SLC1A2 4462/4885SLC1A1 4654/4885 |
| US-20170334914-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | PRKCZ, PIK3CD, PRKCE | SLC1A3 3731/4885SLC1A2 3833/4885SLC1A1 3851/4885 |
| US-20170266196-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4729/4885SLC1A2 4462/4885SLC1A1 4654/4885 |
| US-20140364447-A1 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS | PRKCZ, PIK3CD, PRKCE | SLC1A3 3731/4885SLC1A2 3833/4885SLC1A1 3851/4885 |
| US-10130635-B2 | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals | CYP4B1, ADH1A, CYP1A2 | SLC1A3 4729/4885SLC1A2 4462/4885SLC1A1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.